ISAR Research Updates
Previously, ISAR Steering Committee (ISC) members voted for 1 fully funded project and 4 academic projects. Henceforth from 2019, the ISC members will vote for 2 fully funded projects.
Research topics prioritized by the ISAR steering committee for 2020:
| What is the impact of co-morbidity in severe asthma? | |
| Define responders and non-responders to biologics and describe their characteristics overall and per biologic. | |
| Describe the clinical outcome before and after biologic treatment by biologic class, by individual biologic, and by subgroups of baseline characteristics. |
Research topic prioritized by the ISAR steering committee for the second year 2019:
Comparative effectiveness across severe asthma biologic classes (Anti-IL5 vs Anti lgE) in patients eligible for both modalities.
Aims:
– To describe severe asthma patients eligible for both Anti-IL5 and Anti-IgE.
– To describe and compare clinical outcomes of patients receiving Anti-IL5 or Anti-IgE versus those maintained on OCS in terms of asthma control, exacerbations, lung function
The following research topics were prioritized during the ISC Closed session for 2019 and are open to researchers to join and lead. Submit your interest through our website or contact your country lead for further details.
Research Topics:
| What is the OCS landscape: annual consumption, prevalence, outcomes and side-effects of long-term OCS users? | |
| Describe the characteristics of severe asthma patients with inflammatory phenotypes and FEV1 <40%? | |
| What is the characterization of health disparities across countries? | |
| What are the criteria for choosing and switching between similar biological treatment options in patients with atopic and non-atopic severe eosinophilic asthma? | |
Research topic prioritized by the ISAR steering committee for the second year 2018:
The Characterization and Comparison of Eosinophilic and Non-Eosinophilic Phenotypes of Severe Asthma
Aims:
To describe and compare the demographic and clinical features of the eosinophilic versus non-eosinophilic severe asthma phenotypes and to investigate the unique clusters of asthma phenotypes in the ISAR.
Group characterization and feasibility numbers were presented at the REG summit 2019 during the ISAR Research Collaborator Meeting.
Research Topics:
Hidden Severe Asthma in Primary Care* | |
Biologics in Severe Asthma: Utilization Patterns, Causes for Discontinuation and Switching and Adverse Outcomes* | |
BRISAR: Biomarker Relatability in ISAR* | |
The Role of Exacerbations on Lung Function Trajectory* | |
Identify Predictors (e.g. biomarkers) of Response to Biologics | |
Hidden Chronic Asthma within the COPD/ACO Population | |
Onset of Asthma in Severe Asthma patients | |
Relationship between Socioeconomic Status and Asthma Outcome | |
*Note: Funded Studies
Research topic prioritized by the ISAR steering committee for the inaugural year 2017:
Demographic and Clinical Characteristics of Severe Asthma Patients Worldwide
Aim:
To describe and compare the demographic and clinical characteristics of the severe asthma population globally
Characteristics described:
Demographic distribution, Medication, Comorbidities, Asthma Control, Eosinophils, and IgE counts, Lung Function, Healthcare Resource Utilization, etc.
4,990 patients from five countries have contributed to this first research project of ISAR.